Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy

BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy with a prognosis that varies with genetic heterogeneity of hematopoietic stem/progenitor cells (HSPCs). Induction chemotherapy with cytarabine and anthracycline has been the standard care for newly diagnosed AML, but about 30% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Ruinan, Ji, Min, Li, Guosheng, Xia, Yuan, Guo, Shouhui, Li, Peng, Sun, Yanping, Lu, Fei, Zhang, Jingru, Zang, Shaolei, Yan, Shuxin, Ye, Jingjing, Xue, Fuzhong, Ma, Daoxin, Sun, Tao, Ji, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828578/
https://www.ncbi.nlm.nih.gov/pubmed/36197314
http://dx.doi.org/10.1002/cncr.34481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828578/
https://www.ncbi.nlm.nih.gov/pubmed/36197314
http://dx.doi.org/10.1002/cncr.34481

Ejemplares similares